

Special Issue

Molecular Mechanisms of Cancer Progression and Recurrence

Message from the Guest Editor

Cancer is a multifaceted disease that involves not just appearance at a single body site, but rather has the potential of spreading throughout body organs through the metastasis process. In addition to that, it poses a number of problems in its treatment, and recurrence is a harsh reality for this disease. Factors within the tumor microenvironment play key roles in the process of recurrence and metastasis. These factors include stroma cells and extracellular matrices. Deregulated processes, due to factors such as genetic mutations, including angiogenesis, tumor suppression, repair mechanisms and cell cycle, contribute to the so-called cancer phenotype. The aim of this Special Issue is to provide a collection of research articles, research letters and reviews that deal with the molecular mechanisms of cancer progression and recurrence. The submitted papers may cover any aspect of cancer biology that deals with these issues (not leaving out the interplay with the immune system). Papers that refer to clinical processes based on targeting any cancer progression and recurrence mechanism will be considered too.

Guest Editor

Dr. Nikos G. Gavalas

Division of Clinical Therapeutics, National and Kapodistrian University of Athens, 157 72 Athens, Greece

Deadline for manuscript submissions

30 November 2024



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/202240

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).